Stem Cells - SMi's second annual conference: achieving success in science and commercialisation.
SMi's second annual Stem Cells conference, held in London, included topics covering research developments in the field of stem cell biology and regenerative medicine. This conference report highlights selected presentations on big pharma's perspective on the field, stem cell-based therapies for chronic liver disease and age-related macular degeneration, and strategies to gain approval for the conduct of clinical trials involving stem cells. Investigational drugs discussed include GRNOPC-1 (Geron Corp).
Lucifero
Diana
D
Thomson Reuters, 77 Hatton Garden, London, UK. diana.lucifero@thomsonreuters.com
D000818:Animals; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D008107:Liver Diseases / Q000628:therapy; D008268:Macular Degeneration / Q000628:therapy; D044968:Regenerative Medicine / Q000379:methods / Q000639:trends; D013119:Spinal Cord Injuries / Q000628:therapy; D033581:Stem Cell Transplantation / Q000379:methods / Q000639:trends*; D013234:Stem Cells / Q000166:cytology*